RT @synovialjoints: Sarilumab (SAR) + 14 wk GC taper demonstrated significant efficacy vs the comparator arm in steroid
Tweet Content
Sarilumab (SAR) + 14 wk GC taper demonstrated significant efficacy vs the comparator arm in steroid refractory PMR patients and improvement in quality of life. Sustained remission was 28.3% SAR vs 10.3% comparator arm. Spiera R Abs#1676 https://t.co/gXGJzbYLHK #ACR22 @RheumNow https://t.co/oZBsRtxMUw
Links
Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multice…
http://bit.ly/3O8GH5d
Show on Archive Page
On
Display in Search Results
On
PDQ
Off